Trials for development of once-a-month injectable, hormonal male contraceptive using dienogest plus testosterone undecanoate: dose standardization, efficacy and reversibility studies in rats



      The study was conducted to test the potential of using dienogest (DNG) plus testosterone undecanoate (TU) in rats for development of a once-a-month injectable male hormonal contraceptive.

      Study Design

      Dose selection studies were initiated with administration of DNG in three different doses of 20, 30 and 40 mg/kg body weight (bw) per week plus TU 25 mg/kg bw once in every 6 weeks. Status of spermatogenesis and sperm count in epididymis was evaluated. The frequency of DNG intervention was later extended to every 2- and 4-week intervals. Mating studies, toxicity and reversibility of spermatogenesis following stoppage of treatment were carried out with DNG 40 mg/kg bw at 4-week intervals.


      Complete arrest of spermatogenesis was observed after 60 days of treatment at all doses of DNG (20, 30 and 40 mg/kg bw per week)+TU. However, weights of testis and accessory sex organs (epididymis, prostate and seminal vesicle) declined significantly 60 days post treatment compared to vehicle-treated controls. Epididymis in the treated animals was completely devoid of sperm. When the frequency of DNG injection (20 mg/kg bw) was extended to once every 15 days, a few immotile and decapitated sperm were observed in the epididymis. With TU treatment unchanged, animals receiving DNG (40 mg/kg bw) once either every 2- or 4-week intervals demonstrated good and uniform arrest of spermatogenesis. DNG 40 mg/kg per 4 weeks+TU also demonstrated a significant rise in germ cell apoptosis in the seminiferous epithelium. There was no significant increase in the serum high-density lipoprotein and low-density lipoprotein levels at the end of 120 days of treatment. Following withdrawal of treatment after 60 or 120 days, qualitative restoration of spermatogenesis was rapid in the former compared to the latter.


      Dienogest plus TU has the potential for development as a monthly injectable showing reversible hormonal male contraception with good efficacy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Guha S.K.
        • Singh G.
        • Ansari S.
        • et al.
        Phase II clinical trial of a vas deferens injectable contraceptive for the male.
        Contraception. 1997; 56: 245-250
        • Kamisschke A.
        • Nieschlag E.
        Progress towards hormonal male contraception.
        Trends Pharmacol Sci. 2004; 25: 49-57
        • World Health Organization
        Task Force on Methods for the Regulation of Male Fertility: contraceptive efficacy of testosterone-induced azoospermia and oligospermia in normal men.
        Lancet. 1990; 336: 955-959
        • World Health Organization
        Task Force on Methods for the Regulation of Male Fertility: contraceptive efficacy of testosterone-induced azoospermia and oligospermia in normal men.
        Fertil Steril. 1996; 65: 821-829
        • Turner L.
        • Conway A.J.
        • Jimenez M.
        • et al.
        Contraceptive efficacy of a depot progestin and androgen combination in men.
        J Clin Endocrinol Metab. 2003; 88: 4659-4667
        • Nieschlag E.
        • Zitzmann M.
        • Kamischke A.
        Use of progestins in male contraception.
        Steroids. 2003; 68: 965-972
        • Gu Y.Q.
        • Tong J.S.
        • Ma D.Z.
        • et al.
        Male hormonal contraception effects of injection of testosterone undecanoate and depo-medroxyprogesterone acetate at eight week interval in Chinese men.
        J Clin Endrcrinol Metab. 2004; 89: 2254-2262
        • Merriggiola M.C.
        • Constantino A.
        • Saad F.
        • et al.
        Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
        J Clin Endocrinol Metab. 2003; 90: 2005-2014
        • Anderson R.A.
        • Van Der Spuy Z.M.
        • Dada O.A.
        • Tregoning S.K.
        • Zinn P.M.
        • et al.
        Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone.
        Hum Reprod. 2002; 17: 2869-2877
        • Gonzalo I.T.
        • Swerdloff R.S.
        • Nelson A.L.
        • et al.
        Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
        J Clin Encrinol Metab. 2002; 7: 3562-3572
        • Kamischke A.
        • Heuermann T.
        • Kruger K.
        • et al.
        An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
        J Clin Endocrinol Metab. 2002; 87: 530-539
        • Shrivastava A.
        • Maikhuri J.P.
        • Setty B.S.
        Evaluation of STS 557 as an oral contraceptive in male rat.
        Contraception. 1987; 36: 254-272
        • Chaudhary J.
        • Sharma R.K.
        • Majumdar S.S.
        • Bhatti D.P.S.
        • Misro M.M.
        • Das R.P.
        Effect of STS 557 (17��-cyanomethyl 17 �� hydroxyl estra-4, 9 (10)-dien-3-one) on blood hormone levels, the testis, accessory sex organs and fertility of rats.
        Int J Androl. 1990; 13: 398-407
        • Sharma R.K.
        • Das R.P.
        Effects of STS 557 and 20 AET-1 on sperm functions and serum levels of testosterone in bonnet monkeys.
        Contraception. 1992; 45: 483-491
        • World Health Organization
        Laboratory manual for the examination of human semen and sperm-cervical mucus interaction.
        4th ed. Cambridge University Press, Cambridge, UK1999
        • Russell L.D.
        • Clermont Y.
        Degeneration of germ cells in normal, hypophysectomized and hormone treated hypophysectomized rats.
        Anat Rec. 1977; 187: 347-366
        • Abercrombie M.
        Estimation of nuclear population from microtome sections.
        Anat Rec. 1946; 94: 239-247
        • Clermont Y.
        • Morgantaler H.
        Quantitative study of spermatogenesis in the hypophysectomized rat.
        Endocrinology. 1955; 57: 369-382
        • Matthiesson L.
        • Mclachlan R.I.
        Male hormonal contraception: concept proven, product insight.
        Hum Reprod Upd. 2006; 12: 463-482
        • McLachlan R.I.
        • Robertson D.M.
        • Pruysers E.
        • et al.
        Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
        J Clin Endocrinol Metab. 2004; 89: 142-149
        • El Shannawy A.
        • Gates R.
        • Russel L.
        Hormonal regulation of spermatogenesis in the hypophysectomized rat: cell viability after hormonal replacement in adults after intermediate periods of hypophysectomy.
        J Androl. 1998; 19: 320-334
        • Meriggiola M.C.
        • Costantino A.
        • Bremner W.J.
        • Morselli-Labate A.M.
        Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen.
        J Androl. 2002; 23: 684-690
        • Handelsman D.J.
        • Spaliviero J.A.
        • Simpson J.M.
        • Allan C.M.
        • Singh J.
        Spermatogenesis without gonadotropins: maintenance has a lower testosterone threshold than initiation.
        Endocrinol. 1999; 140: 3938-3946
        • Amory J.K.
        • Page S.T.
        • Bremner W.J.
        Drug insight: recent advances in male hormonal contraception.
        Nat Clin Pract Endocrinol Metab. 2006; 2: 32-41
        • Beebb R.A.
        • Anawalt B.D.
        • Christensen R.B.
        • Paulsen C.A.
        • Bremer W.J.
        • Matsumoto A.M.
        Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
        J Clin Endocrinol Metab. 1996; 81: 757-762
        • Anawalt B.D.
        • Herbst K.L.
        • Matsumoto A.M.
        • Mulders T.M.
        • Coelingh-Bennink H.J.
        • Bremner W.J.
        Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high density lipoprotein suppression.
        Fertil Steril. 2000; 74: 707-714
        • Kinniburgh D.
        • Zhu H.
        • Cheng L.
        • Kicman A.T.
        • Baird D.T.
        • Anderson R.A.
        Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men.
        Hum Reprod. 2002; 17: 1490-1501
        • Brady B.M.
        • Amory J.K.
        • Perheentupa A.
        • et al.
        A multicentric study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.
        Hum Reprod. 2006; 21: 285-294
        • Kamischke A.
        • Diebacker J.
        • Nieschlag E.
        Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function.
        Clin Endocrinol. 2000; 53: 43-52
        • Meriggiola M.C.
        • Bremner W.J.
        • Costantino A.
        • et al.
        Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men.
        J Clin Endocrinol Metab. 2002; 87: 2107-2113
        • Hair W.M.
        • Wu F.C.W.
        Male contraception: prospects for the mew millennium.
        Asian J Androl. 2000; 2: 3-12
        • Gu Y.Q.
        • Wang X.H.
        • Xu D.
        • et al.
        A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.
        J Clin Endocrinol Metab. 2003; 88: 562-568
        • Anderson R.A.
        • Zhu H.
        • Cheng L.
        • Baird D.T.
        Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants.
        Contraception. 2002; 66: 357-364
        • Chaki S.P.
        • Misro M.M.
        • Gautam D.K.
        • Kaushik M.
        • Ghosh D.
        • Chainy G.B.
        Estradiol treatment induces testicular oxidative stress and germ cell apoptosis in rats.
        Apoptosis. 2006; 11: 1427-1437
        • Chaki S.P.
        • Ghosh D.
        • Misro M.M.
        Simultaneous increase in germ cell apoptosis and oxidative stress under acute unilateral testicular ischemia in rats.
        Intl J Androl. 2003; 26: 319-328
        • Chaki S.P.
        • Misro M.M.
        • Ghosh D.
        • Gautam D.K.
        • Srinivas M.
        Apoptosis and cell removal in the cryptorchid rat testis.
        Apoptosis. 2005; 10: 395-406